Strengthen the research of medication for the treatment of nontuberculous mycobacterial disease / 中华临床感染病杂志
Chinese Journal of Clinical Infectious Diseases
; (6): 174-182, 2023.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-993729
Responsible library:
WPRO
ABSTRACT
The global trends of nontuberculous mycobacteria (NTM) infection and disease are both rising. Nontuberculous mycobacterial disease(NTMD) is a worldwide health burden associated with increasing morbidity, mortality, and economic costs. Antibiotic therapy is the mainstay of treatment for NTMD.Mycobacterial pathogens are intrinsically resistant to many available antibiotics, making treatment extremely challenging, especially in immunocompromised individuals and patients with underlying chronic lung conditions. Even with lengthy therapy and the use of a combination of antibiotics, only less than half NTMD patients can achieve clinical treatment success, so it is urgent to develop novel anti-NTM antibiotics. This article reviews the research progress on the medication of nontuberculous mycobacterial diseases.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.8 Achieve universal access to health
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Clinical Infectious Diseases
Year:
2023
Document type:
Article